FOXM1 and thyroid gland carcinoma: Overall, our work sheds new light on the role of FOXE1 in thyroid cancer susceptibility, and the transcriptional partnership between FOXE1 and ELK1 opens new therapeutic possibilities, either via targeting of FOXE1-ELK1 binding (in a similar manner to the targeting of FOXM1 which is currently undergoing preclinical investigation [60]), or via modulating of ELK1 phosphorylation (e.g. as we have shown here using MEK inhibition).